Advertisement

Journal of Neural Transmission

, Volume 107, Issue 12, pp 1475–1481 | Cite as

No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia

  • M. Rainer
  • E. Kraxberger
  • M. Haushofer
  • H. A. M. Mucke
  • K. A. Jellinger
Short Communication

Summary.

Reduced nicotinamide adenine dinucleotide (NADH) is advertised as an over-the-counter product or dietary supplement to treat Alzheimer's disease. We performed a 3-month open-label study with oral 10 mg/day NADH with 25 patients with mild to moderate dementia of the Alzheimer, vascular, and fronto-temporal types in addition to their current cholinomimetic drug medication. In 19 patients who completed the study, we found no evidence for any cognitive effect as defined by established psy-chometric tests. We conclude that NADH is unlikely to achieve cognitive improvements in an extent reported earlier, and present theoretical arguments against an effectiveness of this compound in dementia disorders.

Keywords: Alzheimer disease dementia nicotinamide adenosine dinucleotide blood brain barrier open clinical trial. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • M. Rainer
    • 1
  • E. Kraxberger
    • 1
  • M. Haushofer
    • 1
  • H. A. M. Mucke
    • 2
  • K. A. Jellinger
    • 3
  1. 1.Memory-Clinic and Psychiatric Department, Donauspital, Sozialmedizinisches Zentrum Ost,
  2. 2.H.M. Pharma Consultancy, and
  3. 3.Ludwig Boltzmann-Institute for Clinical Neurobiology, Vienna, AustriaAT

Personalised recommendations